Edition: Australia  
One News Page
“Probably the fastest-access news portal in the world”
> >

Israel's Gamida Cell raises $40 million for bone marrow trial

Reuters India Monday, 19 June 2017 ()
TEL AVIV (Reuters) - Israel's Gamida Cell, which is developing cellular therapies to treat cancer and rare genetic diseases, said on Monday it raised $40 million to finance the advanced trial of its product NiCord to facilitate bone marrow transplants.
Share on
Share on
Post on 
Share by

Recent related news

Paradigm Biopharmaceuticals CEO buys shares on-market

Paradigm Biopharmaceuticals (ASX:PAR) has received a vote of confidence from its CEO and director, Paul Rennie, who has purchased $100,618.95 worth of shares...
Proactive Investors - Business

Regeneus to receive cash payment for trial success

Regeneus (ASX:RGS) is set to receive a milestone payment of US$1 million for meeting the primary endpoints of its Phase 1 safety trial of Progenza in patients...
Proactive Investors - Business

You Might Like

Other recent news in Health

22 million Americans would become uninsured under Senate health-care bill, CBO estimatesCANADA nurse Elizabeth Wettlaufer jailed for life for murders
MEDICAID rollback may up the risk of advanced stage breast cancer diagnosesCBO projects SENATE HEALTH BILL would drive up number of uninsured
Linde's Lincare settles U.S. whistleblower case for $20 MILLIONStudy: HEALTH INSURANCE saves lives
Few players screened for concussions in last soccer WORLD CUPCHARLIE GARD parents lose European court appeal
New form of Roche's Esbriet approved in EUROPE for lung disorderDrinking water in NORTH CAROLINA being tested for toxic substance


Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2017 One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter   FIND us on Google+